AOD-9604 is a modified fragment of human growth hormone that has attracted significant research interest specifically for its fat metabolism effects — and notably for what it doesn’t do. Unlike full-length GH or many other peptides that affect insulin sensitivity and blood glucose, AOD-9604 appears to target fat cells selectively, making it one of the more targeted research compounds in the metabolic space.
What Is AOD-9604?
AOD-9604 (Anti-Obesity Drug 9604) is a synthetic fragment of human growth hormone, specifically corresponding to amino acids 176–191 of the hGH C-terminus, with an additional tyrosine at the N-terminus for stability. It was developed by Metabolic Pharmaceuticals in Australia and has undergone Phase I–IIb clinical trials for obesity treatment.
The key design principle: the C-terminal fragment of hGH contains the region responsible for fat metabolism effects, while the N-terminal region drives the anabolic, IGF-1-stimulating, and insulin-desensitizing effects. AOD-9604 isolates the metabolic region while eliminating the growth-promoting and glucose-disrupting properties of full HGH.
Mechanism of Action
Lipolysis Stimulation: AOD-9604 stimulates lipolysis — the breakdown of stored triglycerides in fat cells — through a mechanism similar to full-length GH but without activating IGF-1 production or affecting insulin sensitivity.
Lipogenesis Inhibition: Simultaneously inhibits lipogenesis (the conversion of non-fat nutrients into stored fat), creating a dual effect that shifts the body’s fat balance toward net reduction.
Beta-3 Adrenoreceptor Activity: Research suggests AOD-9604 may activate beta-3 adrenergic receptors in adipose tissue, which are directly involved in thermogenesis and fat oxidation — the same receptors targeted by many experimental anti-obesity compounds.
No IGF-1 Stimulation: A critical distinction — AOD-9604 does not significantly elevate IGF-1 or affect glucose metabolism at research doses, avoiding the insulin resistance associated with full GH administration.
Clinical Research Findings
Phase I Trials: AOD-9604 demonstrated safety and tolerability across multiple dose levels in healthy volunteers. No significant effects on blood glucose, insulin levels, or IGF-1 were observed — confirming the selective metabolic profile.
Phase IIa: A 12-week randomized controlled trial showed that AOD-9604 (1mg orally daily) produced statistically significant reductions in body weight compared to placebo — particularly in abdominal fat. The oral bioavailability of AOD-9604 is an unusual advantage in the peptide space.
Phase IIb: Larger trials showed more modest effects, and the drug did not proceed to Phase III for obesity indication. However, the safety and mechanistic data remain valuable for research purposes.
Cartilage Research: Interestingly, subsequent research has explored AOD-9604 for cartilage and joint repair. In vitro and animal studies show it may stimulate cartilage cell production and reduce inflammation in osteoarthritis models — an unexpected application that has generated significant research interest.
AOD-9604 vs. Other Fat Loss Research Peptides
| Peptide | Mechanism | IGF-1 Effect | Glucose Effect |
|---|---|---|---|
| AOD-9604 | Direct lipolysis, lipogenesis inhibition | None | None |
| Full HGH | Lipolysis + anabolic effects | Significant increase | Insulin resistance |
| Semaglutide | Appetite suppression, metabolic | None | Improves glucose |
| MK-677 | GH secretagogue, body composition | Significant increase | Mild resistance |
Conclusion
AOD-9604’s selective fat metabolism profile — lipolysis stimulation without IGF-1 elevation or glucose disruption — makes it a scientifically interesting research tool for studying adipose biology and fat metabolism independently of GH’s anabolic and metabolic effects. The emerging cartilage research adds an unexpected dimension to its research profile. Combat Research provides pharmaceutical-grade AOD-9604 for research applications.
For research purposes only. Not for human therapeutic use.
Related Research Articles
Shop Research Peptides at Combat Research
Combat Research carries a full range of research peptides including metabolic compounds, GH fragments, and more. All ≥99% purity, USA domestic.
